Therefore, we believe that MSCs that were injected in B16F10-treated mice during the progressive stage of melanoma growth adopted immunosuppressive MSC2 phenotype and in a TGF-β and IL-10-dependent manner attenuated antitumor immune response, resulting in increased melanoma growth. The gene discussed is TGFB1; the disease is melanoma.